CSNpharm

CSNpharm logo

Csnpharm is committed to providing you with high quality products and outstanding services. We supply over 5000 bioactive compounds in stock, including inhibitors, agonists and natural products for laboratory and scientific use. Csnpharm has always been committed to develop quality products that are validated by NMR, UPLC, LC-MS, GC, Chiral HPLC and so on. We have a professional technical support team for customer service with years of experience in life science. Csnpharm is your reliable partner for scientific research.

Company Website

Product Listing

XMD16-5 5mg  | ≥99%

CSNpharm

XMD16-5 is an inhibitor of TNK2 with IC50 value of 0.38µM, potently inhibiting phosphorylation of TNK2 truncation mutations found in solid tumor types.

More Information Supplier Page

XMD16-5 1mg  | ≥99%

CSNpharm

XMD16-5 is an inhibitor of TNK2 with IC50 value of 0.38µM, potently inhibiting phosphorylation of TNK2 truncation mutations found in solid tumor types.

More Information Supplier Page

XMD16-5 10mg  | ≥99%

CSNpharm

XMD16-5 is an inhibitor of TNK2 with IC50 value of 0.38µM, potently inhibiting phosphorylation of TNK2 truncation mutations found in solid tumor types.

More Information Supplier Page

XRK3F2 10mg  | ≥99%

CSNpharm

XRK3F2 is a p62-ZZ domain inhibitor which can blunt MM-induced Runx2 suppression and induce new bone formation and remodeling.

More Information Supplier Page

XRK3F2 100mg  | ≥99%

CSNpharm

XRK3F2 is a p62-ZZ domain inhibitor which can blunt MM-induced Runx2 suppression and induce new bone formation and remodeling.

More Information Supplier Page

XRK3F2 5mg  | ≥99%

CSNpharm

XRK3F2 is a p62-ZZ domain inhibitor which can blunt MM-induced Runx2 suppression and induce new bone formation and remodeling.

More Information Supplier Page

XRK3F2 50mg  | ≥99%

CSNpharm

XRK3F2 is a p62-ZZ domain inhibitor which can blunt MM-induced Runx2 suppression and induce new bone formation and remodeling.

More Information Supplier Page

XRK3F2 25mg  | ≥99%

CSNpharm

XRK3F2 is a p62-ZZ domain inhibitor which can blunt MM-induced Runx2 suppression and induce new bone formation and remodeling.

More Information Supplier Page

XY1 10mg  | ≥99%

CSNpharm

XY1 is a negative control of SGC 707 which works as a potent and selective allosteric inhibitor of PRMT3, while XY1 shows almost no activity.

More Information Supplier Page

XY1 50mg  | ≥99%

CSNpharm

XY1 is a negative control of SGC 707 which works as a potent and selective allosteric inhibitor of PRMT3, while XY1 shows almost no activity.

More Information Supplier Page

XY1 5mg  | ≥99%

CSNpharm

XY1 is a negative control of SGC 707 which works as a potent and selective allosteric inhibitor of PRMT3, while XY1 shows almost no activity.

More Information Supplier Page

Xylometazoline HCl 1g  | ≥99%

CSNpharm

Xylometazoline HCl a direct acting sympathomimetic adrenergic α-agonist, used to improve symptoms of nasal congestion, allergic rhinitis, and sinusitis with elimination half-life‎ of ‎>10 seconds.

More Information Supplier Page

Xylometazoline HCl 100mg  | ≥99%

CSNpharm

Xylometazoline HCl a direct acting sympathomimetic adrenergic α-agonist, used to improve symptoms of nasal congestion, allergic rhinitis, and sinusitis with elimination half-life‎ of ‎>10 seconds.

More Information Supplier Page

Xylose 25mg  | ≥99%

CSNpharm

Xylose, a natural product, can be catalyzed into xylulose by xylose isomerase, and it is the key step for anaerobic ethanolic fermentation of xylose. Can be used as an excipient in cosmetics and pharmaceuticals.

More Information Supplier Page

Xylose 100mg  | ≥99%

CSNpharm

Xylose, a natural product, can be catalyzed into xylulose by xylose isomerase, and it is the key step for anaerobic ethanolic fermentation of xylose. Can be used as an excipient in cosmetics and pharmaceuticals.

More Information Supplier Page

Y-27632 50mg  | ≥98%

CSNpharm

Y-27632 is an ATP-competitive inhibitor of ROCK-I and ROCK-II, with Ki of 220 nM and 300 nM for ROCK-I and ROCK-II, respectively.

More Information Supplier Page

Y-27632 10mg  | ≥98%

CSNpharm

Y-27632 is an ATP-competitive inhibitor of ROCK-I and ROCK-II, with Ki of 220 nM and 300 nM for ROCK-I and ROCK-II, respectively.

More Information Supplier Page

Y-27632 100mg  | ≥98%

CSNpharm

Y-27632 is an ATP-competitive inhibitor of ROCK-I and ROCK-II, with Ki of 220 nM and 300 nM for ROCK-I and ROCK-II, respectively.

More Information Supplier Page

Y-27632 1mg  | ≥98%

CSNpharm

Y-27632 is an ATP-competitive inhibitor of ROCK-I and ROCK-II, with Ki of 220 nM and 300 nM for ROCK-I and ROCK-II, respectively.

More Information Supplier Page

Y-27632 5mg  | ≥98%

CSNpharm

Y-27632 is an ATP-competitive inhibitor of ROCK-I and ROCK-II, with Ki of 220 nM and 300 nM for ROCK-I and ROCK-II, respectively.

More Information Supplier Page

Y-27632 2HCl 10mg  | ≥99%

CSNpharm

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.

More Information Supplier Page

Y-27632 2HCl 5mg  | ≥99%

CSNpharm

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.

More Information Supplier Page

Y-27632 2HCl 250mg  | ≥99%

CSNpharm

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.

More Information Supplier Page

Y-27632 2HCl 50mg  | ≥99%

CSNpharm

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.

More Information Supplier Page

Y-27632 2HCl 100mg  | ≥99%

CSNpharm

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.

More Information Supplier Page

Y-27632 2HCl 1mg  | ≥99%

CSNpharm

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM, exhibits > 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.

More Information Supplier Page

Y-33075 25mg  | ≥98%

CSNpharm

Y-33075 is potent and selective p160 ROCK inhibitor with an Ki value of 0.14 μM, > 200 fold selectivity for p160ROCK than PKC, cAMP-dependent protein kianse and Mypsin light-chain kinase.

More Information Supplier Page

Y-33075 50mg  | ≥98%

CSNpharm

Y-33075 is potent and selective p160 ROCK inhibitor with an Ki value of 0.14 μM, > 200 fold selectivity for p160ROCK than PKC, cAMP-dependent protein kianse and Mypsin light-chain kinase.

More Information Supplier Page

Y-33075 1mg  | ≥98%

CSNpharm

Y-33075 is potent and selective p160 ROCK inhibitor with an Ki value of 0.14 μM, > 200 fold selectivity for p160ROCK than PKC, cAMP-dependent protein kianse and Mypsin light-chain kinase.

More Information Supplier Page

Y-33075 5mg  | ≥98%

CSNpharm

Y-33075 is potent and selective p160 ROCK inhibitor with an Ki value of 0.14 μM, > 200 fold selectivity for p160ROCK than PKC, cAMP-dependent protein kianse and Mypsin light-chain kinase.

More Information Supplier Page

Y-33075 10mg  | ≥98%

CSNpharm

Y-33075 is potent and selective p160 ROCK inhibitor with an Ki value of 0.14 μM, > 200 fold selectivity for p160ROCK than PKC, cAMP-dependent protein kianse and Mypsin light-chain kinase.

More Information Supplier Page

Y15 50mg  | ≥98%

CSNpharm

Y15 is a small molecule FAK phosphorylation inhibitor which specifically block phosphorylation of Y397-FAK and total phosphorylation of FAK.

More Information Supplier Page

Yatein 5mg  | ≥98%

CSNpharm

Yatein, a lignan precursor of podophyllotoxin isolated and purified from the leaves of Chamaecyparis obtusa, is a key agent in anticancer drugs and can significantly suppress HSV-1 multiplication in HeLa cells without apparent cytotoxicity.

More Information Supplier Page